Chiron Corporation

Denka Seiken Co., Ltd.

The Director General of the National Institute of Health of Japan

Japan As Represented by Director-general National Institute of Infectious Diseases

Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Tokyo Metropolitan Institute of Medical Science

Japan As Represented by Director General of Agency of National Institute

University of California

Toray Industries, Inc.

Mitsubishi Pharma Corporation

Japan As Represented by Director-general of National Institute of Infectious Diseases

Japan As Represented by the Director General of the Agency of National

Tokyo Metropolitan Organization for Medical Research

Japan As Represented by the Director-general of National Institute of Infectious Diseases

Tatsuo Miyamura

Izumu Saito

Yoshiharu Matsuura

Shizuko Harada

Naokazu Takeda

Yoshikazu Honda

Toshinori Sato

Kunio Kamata

Makoto Seki

Katsuro Natori

Seiya Sato

Izumi Saito

Joe Chiba

Michael Houghton

Tetsuro Suzuki

Takaji Wakita

Koji Ishii

Amy J Weiner

Jang Hyun Han

Janice A Kolberg

Bruce D Irvine

Tai-An Cha

Saburo Sone

Jun-ichi Tanabe

Ryosuke Suzuki

R Holland Cheng

Li Xing

Yasuhiro Yasutomi

Seima Itami

Tian-Cheng Li

Yoshihisa Yotsumoto

Tatsurou Shibui

Jun-Ichi c/o Pharmaceutical Research Laboratories Tanabe

Takaji c/o Department Of Virology Ii National Institute Wakita

Takaji c/o Department Of Virology Ii Wakita

This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.

Multiple antigen delivery system using hepatitis E virus-like particle

A polynucleotide base sequence represented by SEQ ID NO: 22, a vector containing the polynucleotide and a method of preparing a small round structure virus (SRSV) virus-like particle in insect cells with vector.

SRSV detection kit

The present invention relates to a method for producing a recombinant hepatitis C virus-like particle comprising the steps of introducing into (i) a cell in which an RNA replicon comprising a nucleotide sequence comprising the 5' untranslated region, the nucleotide sequence coding for the NS3, NS4A, NS4B, NS5A, and NS5B proteins, and the 3&#x2032; untranslated region of a genome RNA derived from a hepatitis C virus strain autonomously replicates, (ii) a vector expressing the Core, E1, E2, and p7 proteins derived from a hepatitis C virus strain that is the same as or different from that as defined in the above (i), culturing the cell, and recovering the produced virus-like particle, and a recombinant hepatitis C virus particle produced by this method.

Recombinant human hepatitis C virus-like particle and method for producing the same

The present invention relates to a method for producing infectious hepatitis C virus (HCV) particles, comprising a step of introducing an expression vector into a cell that allows HCV proliferation, such expression vector comprising: DNA sequences encoding the 5' untranslated region, structural proteins, and, if necessary, non-structural proteins of HCV and DNA sequences encoding non-structural proteins and the 3&#x2032; untranslated region derived from the HCV JFH1 strain, which are located downstream of a polymerase I promoter; and a DNA fragment containing an RNA polymerase I terminator, which is located further downstream thereof.

High production system for infectious hepatitis C virus particle

This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related virus constituting peptides selected from the following peptide groups (a) to (k), respectively: (a) a peptide having an amino acid sequence represented by SEQ ID NO: 1, and the like, (b) a peptide having an amino acid sequence represented by SEQ ID NO: 2, and the like, (c) a peptide having an amino acid sequence represented by SEQ ID NO: 3, and the like, (d) a peptide having an amino acid sequence represented by SEQ ID NO: 4, and the like, (e) a peptide having an amino acid sequence represented by SEQ ID NO: 5, and the like, (f) a peptide having an amino acid sequence represented by SEQ ID NO: 6, and the like, (g) a peptide having an amino acid sequence represented by SEQ ID NO: 7, and the like, (h) a peptide having an amino acid sequence represented by SEQ ID NO: 8, and the like, (i) a peptide having an amino acid sequence represented by SEQ ID NO: 9, and the like, (j) a peptide having an amino acid sequence represented by SEQ ID NO: 10, and the like, and (k) a peptide having an amino acid sequence represented by SEQ ID NO: 11, and the like. Use of the kit makes it possible to detect most SRSV-related viruses and further to distinguish their serotypes and genogroups, easily and surely.

The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.

Remedies for hepatitis C

This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related which makes it possible to detect most SRSV-related viruses and further to distinguish their serotypes and genogroups.

Small round structured virus (SRSV) detection kit

A method for extracellularly producing an ectoprotein of hepatitis C virus comprises the steps of cultivating a transformant which is transformed with an expression vector containing a DNA fragment coding for the ectoprotein of hepatitis C virus and recovering the ectoprotein of hepatitis C virus extracellularly produced by the transformant. The protein originated from the E1 region prepared by the method can be used as a material for preparing a vaccine for preventing HCV infection. In addition, a diagnostic agent containing the protein is useful for the detection of an HCV antibody or the confirmation of the presence thereof in sera or the like. In other words, the protein of the present invention permits the diagnosis of C type hepatitis in high specificity and sensitivity.

Method for producing ectoprotein of hepatitis C virus

Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.

HCV isolates

Hepatitis C virus isolate polypeptides

Method of producing ectoprotein of hepatitis C virus

A diagnostic reagent for hepatitis C, which detects an antibody induced by infection of hepatitis C virus, and comprises the second envelope protein or first non-structural protein which is encoded by the gene of hepatitis C virus and has a sugar chain. This invention also provide a method for detecting an anti-hepatitis C virus antibody. The use of the diagnostic reagent for hepatitis C according to the present invention makes highly sensitive diagnosis of hepatitis C possible.

Diagnostic reagent for hepatitis C

Growing community of inventors

Tokyo, Japan

Tatsuo Miyamura